Synthesis and Biological Evaluation of 1,2,3-triazole tethered Pyrazoline and Chalcone Derivatives. 2016

Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
Medicinal Chemistry and Pharmacology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500607, India.

A series of pyrazoline derivatives and corresponding chalcone intermediates with substituents same as combretastatin-A4(CA-4) conjugated with triazole nucleus has been synthesized and evaluated for their anticancer potential. Sulphorhodamine B(SRB) assay indicated compound 12c to be the most active compound from the series with GI50 value of 6.7 μm against the human liver carcinoma cell line HepG2. Interestingly, the intermediate 11c exhibited more promising cytotoxicity demonstrating GI50 value of 1.3 μm against the prostate cancer cell line DU145. Compounds 11c and 12c caused accumulation of cells in G2/M phase and inhibited tubulin polymerization. Furthermore, these compounds reduce the mitochondrial membrane potential and activate caspases 3 and 9, thereby indicating their ability to trigger apoptosis.

UI MeSH Term Description Entries
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin

Related Publications

Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
January 2012, European journal of medicinal chemistry,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
August 2020, Bioorganic & medicinal chemistry letters,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
October 2021, Chemistry & biodiversity,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
August 2021, Pharmaceuticals (Basel, Switzerland),
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
August 2017, Bioorganic & medicinal chemistry letters,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
November 2016, European journal of medicinal chemistry,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
January 2018, MedChemComm,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
April 2015, Bioorganic chemistry,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
October 2021, ACS omega,
Syed Mohammed Ali Hussaini, and Poornachandra Yedla, and Korrapati Suresh Babu, and Thokhir B Shaik, and Ganesh Kumar Chityal, and Ahmed Kamal
December 2020, Bioorganic chemistry,
Copied contents to your clipboard!